Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors)-Reference-Cited by-同舟云学术

Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors)

Published:2023 Issue: Volume:56 Page:
ISSN:1678-9849
Container-title:Revista da Sociedade Brasileira de Medicina Tropical
language:
Short-container-title:Rev. Soc. Bras. Med. Trop.

Author:

Bonifácio Lívia Pimenta¹^ORCID,Ramacciotti Eduardo²^ORCID,Agati Leandro Barile^ORCID,Vilar Fernando Crivelenti¹^ORCID,Silva Anna Christina Tojal da¹^ORCID,Louzada Júnior Paulo¹^ORCID,Fonseca Benedito Antônio Lopes da¹^ORCID,Souza Hayala Cristina Cavenague de¹^ORCID,Oliveira Caroline Candida Carvalho de²^ORCID,Aguiar Valéria Cristina Resende²^ORCID,Quadros Carlos Augusto de Aguiar³^ORCID,Dusilek Cesar⁴^ORCID,Itinose Kengi⁴^ORCID,Risson Ricardo⁴^ORCID,Ferreira Lucas Roberto Rivabem⁴^ORCID,Lopes Renato Delascio⁵^ORCID,Kallas Esper Georges¹^ORCID,Bellissimo-Rodrigues Fernando¹^ORCID

Affiliation:

1. Universidade de São Paulo, Brasil

2. Science Valley Research Institute, Brasil; Grupo Leforte, Brasil

3. Grupo Leforte, Brasil

4. Hospital do Rocio, Brasil

5. Brazilian Clinical Research Institute, Brasil; Duke University Medical Center, USA

Publisher

FapUNIFESP (SciELO)

Subject

Infectious Diseases,Microbiology (medical),Parasitology

Link

http://www.scielo.br/scielo.php?script=sci_pdf&pid=S0037-86822023000100317&tlng=en